Huateng Pharma to Detail High-Purity PEG Derivatives and Chemical Synthesis Services at CPHI China 2026 - Labinsights

Huateng Pharma to Detail High-Purity PEG Derivatives and Chemical Synthesis Services at CPHI China 2026

icon.highlightedarticle.dark R&D
26 May 2026
Huateng Pharma to Detail High-Purity PEG Derivatives and Chemical Synthesis Services at CPHI China 2026
Huateng Pharma to Detail High-Purity PEG Derivatives and Chemical Synthesis Services at CPHI China 2026 | Photo: Huateng Pharma

Huateng Pharma will present its latest chemical synthesis capabilities and polyethylene glycol (PEG) derivative manufacturing parameters at CPHI China 2026. Laboratory professionals, research scientists, and process engineers are invited to connect with the technical team at Booth W3P16 from June 16-18 at the Shanghai New International Expo Center.

For R&D teams developing complex therapeutics—including antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and mRNA vaccines—precise, high-purity raw materials are a baseline requirement. Huateng Pharma manufactures GMP-grade PEG derivatives engineered to support projects from initial laboratory research through to full commercialization, with batch capabilities scaling from single grams up to 100 kilograms.

A primary focus for the analytical and production teams is minimizing variability in structural composition. The manufacturing protocols are strictly controlled to maintain high purity PEG, ensuring consistency for sensitive laboratory applications. The featured catalog at the exhibition includes:

  • Polydispersed PEGs: Molecular weights ranging from 200 to 43KDa.
  • Monodispersed PEGs: Discrete chain lengths from 1 to 48 units.
  • Multi-Arm PEGs: Specialized architectures for targeted delivery systems.

“In laboratory environments, the consistency of chemical inputs directly impacts the viability of downstream applications,” said Dr. Deng, a scientist at Huateng Pharma. “By controlling our PEG’s high purity, we provide researchers with the analytical certainty required to transition formulations from benchtop experiments to large-scale production.”

Beyond PEG derivatives, Huateng Pharma provides comprehensive Contract Development and Manufacturing Organization (CDMO) services. The laboratory and engineering divisions support custom synthesis, process optimization, and the production of pharmaceutical intermediates, cosmetic ingredients, and specialty chemicals. The team will be available to discuss technical data and manufacturing support for compounds including:

  • Methacrylonitrile (CAS: 126-98-7)
  • Diethyl chloromalonate (CAS: 14064-10-9)
  • Tetrahydrocurcumin (CAS: 36062-04-1)
  • 4-Methylpyrazole (CAS: 7554-65-6)
  • 4-(Tert-butyl)-1,2-phenylene dibenzoate (CAS: 1232839-88-1)
  • Piroctone olamine (CAS: 68890-66-4)
  • Diethylamino hydroxybenzoyl hexyl benzoate (CAS: 302776-68-7)
  • Methyl-3-(4-bromomethyl)cinnamate (CAS: 946-99-6)
  • 2-Methyl-5-bromobenzoic acid (CAS: 79669-49-1)

Attendees representing analytical laboratories, CROs, and pharmaceutical manufacturers can schedule technical consultations in advance or visit the booth during the exhibition.

Event Details:

  • Exhibition: CPHI China 2026
  • Dates: June 16-18, 2026
  • Location: Shanghai New International Expo Center
  • Booth Number: W3P16

About Huateng Pharma

Huateng Pharma is a global chemical manufacturer supplying high-quality PEG derivatives and comprehensive CDMO services. The company supports laboratories, biotechnology firms, and pharmaceutical companies with scalable chemical synthesis, spanning from research grade materials to commercial manufacturing.

Written by

Hunan Huateng Pharmaceutical Co. Ltd

Read more